Amgen, Inc.
http://www.amgen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amgen, Inc.
Amgen’s Lumakras: FDA Flags ‘Marginal’ Efficacy Results, Potential Systemic Bias In Lung Cancer Trial
Company seeks conversion from accelerated to regular approval for the first KRAS G12C inhibitor on the market, but the agency is asking its Oncologic Drugs Advisory Committee whether the progression-free survival primary endpoint in the CodeBreaK 200 confirmatory trial can be reliably interpreted.
Accelerated Approvals: Conversions Still Outweigh Withdrawals, But Takeda’s Exkivity Brings 2023’s Pull Count To Six
US FDA’s Oncologic Drugs Advisory Committee will convene in November for a ‘general discussion about delayed confirmatory trials’ and the ‘continued optimization of the accelerated approval process.’
Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.
Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?
Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Abgenix
- Amgen Astellas BioPharma K.K.
- Amgen K.K.
- Avidia
- BioVex Group
- Catherex, Inc.
- ChemoCentryx, Inc.
- deCODE Genetics
- Dezima Pharma B.V.
- Five Prime Therapeutics, Inc.
- Ilypsa
- Immunex Corporation
- KAI Pharmaceuticals
- Kirin-Amgen Inc.
- Laboratorio Quimico Farmaceutico Bergamo Ltd
- Micromet, Inc. (CancerVax Corporation)
- Nuevolution AB
- Nuevolution A/S
- Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
- Saga Investments LLC
- Tularik
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice